Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $2,500,287 | $1,415,319 | $1,075,815 |
| - Cash | $141,789 | $118,316 | $151,890 |
| + Debt | $11,831 | $2,034 | $0 |
| Enterprise Value | $2,370,329 | $1,299,037 | $923,925 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| EBITDA | -$216,681 | -$74,967 | -$39,785 |
| % Margin | – | – | – |
| Net Income | -$182,146 | -$83,985 | -$39,785 |
| % Margin | – | – | – |
| EPS Diluted | -3.3 | -1.66 | -0.79 |
| % Growth | -98.8% | -110.1% | – |
| Operating Cash Flow | -$171,174 | -$74,761 | -$16,427 |
| Capital Expenditures | -$1,152 | -$167 | $0 |
| Free Cash Flow | -$172,326 | -$74,928 | -$16,427 |